Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19959043 | 0.90 | HRH3 (0.39) | KCNH2CACNA1ICYP2D6CYP1A2ALOX15 | |
| SCHEMBL23664716 | 0.90 | KCNH2 (0.39) | KCNH2CACNA1ICYP2D6CYP1A2ALOX15 | |
| SCHEMBL20317411 | 0.90 | KCNH2 (0.36) | KCNH2CACNA1ICYP2D6CYP1A2ALOX15 | |
| SCHEMBL21933617 | 0.87 | CYP1A2 (0.41) | KCNH2CACNA1ICYP2D6CYP1A2ALOX15 | |
| SCHEMBL15199142 | 0.85 | KCNH2 (0.46) | KCNH2CACNA1IALDH1A1SMN1; SMN2 | |
| SCHEMBL20325063 | 0.84 | KCNH2 (0.39) | KCNH2CACNA1IACHE | |
| SCHEMBL824023 | 0.82 | CARM1 (0.47) | KCNH2CACNA1ICYP2D6CYP1A2MEN1 | |
| SCHEMBL18872031 | 0.82 | KCNH2 (0.43) | KCNH2CACNA1INPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12374964 | 0.82 | KDM1A (0.39) | CYP2D6CYP1A2ALOX15NPC1RAB9A | |
| SCHEMBL21421756 | 0.81 | KCNH2 (0.35) | KCNH2CACNA1ICYP2D6CYP1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | KCNH2 4861/4885CACNA1I 4870/4885CYP2D6 4632/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | KCNH2 4867/4885CACNA1I 4710/4885CYP2D6 4752/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | KCNH2 4850/4885CACNA1I 4439/4885CYP2D6 4827/4885 |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | KCNH2 3892/4885CACNA1I 2783/4885CYP2D6 201/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | KCNH2 4873/4885CACNA1I 4812/4885CYP2D6 4574/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | KCNH2 4861/4885CACNA1I 4870/4885CYP2D6 4632/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | KCNH2 4836/4885CACNA1I 4123/4885CYP2D6 4623/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | KCNH2 4805/4885CACNA1I 4748/4885CYP2D6 4807/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | KCNH2 4712/4885CACNA1I 4452/4885CYP2D6 4738/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | KCNH2 4805/4885CACNA1I 4748/4885CYP2D6 4807/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | KCNH2 4867/4885CACNA1I 4710/4885CYP2D6 4752/4885 |
| US-11834460-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | KCNH2 4858/4885CACNA1I 4612/4885CYP2D6 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.